82 related articles for article (PubMed ID: 6472516)
1. Immunological monitoring of melanoma patients on BCG immunotherapy. I. Enzyme-linked immunosorbent assay of human sera after BCG-treatment.
Kovatchev D; Kolushky V; Engibarov A
Neoplasma; 1984; 31(4):453-8. PubMed ID: 6472516
[TBL] [Abstract][Full Text] [Related]
2. Monitoring immunotherapy with Bacillus Calmette-Guérin by antibody titer.
Wile AG; Sparks FC; Morton DL
Cancer Res; 1977 Jul; 37(7 Pt 1):2251-6. PubMed ID: 324610
[TBL] [Abstract][Full Text] [Related]
3. HLA-B7 associated tuberculin hyporesponsiveness in BCG treated melanoma patients.
Buckley CE; White DH; Seigler HF
Monogr Allergy; 1977; 11():97-105. PubMed ID: 876133
[TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy of malignant melanoma (active specific and non-specific immune stimulation) (author's transl)].
Kokoschka EM; Micksche M
Wien Klin Wochenschr; 1976 Nov; 88(21):690-6. PubMed ID: 1007279
[TBL] [Abstract][Full Text] [Related]
5. Immunological factors which influence response to immunotherapy in malignant melanoma.
Morton D; Eilber FR; Malmgren RA; Wood WC
Surgery; 1970 Jul; 68(1):158-63; discussion 163-4. PubMed ID: 10483463
[TBL] [Abstract][Full Text] [Related]
6. Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.
Zlotta A; Drowart A; van Vooren JP; Simon J; Schulman CC; Huygen K
Acta Urol Belg; 1994 Sep; 62(3):63-8. PubMed ID: 7976857
[TBL] [Abstract][Full Text] [Related]
7. Immunological changes in cancer patients receiving BCG.
Cochran AJ; Mackie RM; Jackson AM; Ogg LJ; Ross CE
Dev Biol Stand; 1977 Apr 13-15; 38():441-8. PubMed ID: 608535
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunological significance of human melanoma cytotoxic antibody.
Bodurtha AJ; Chee DO; Laucius JF; Mastrangelo MJ; Prehn RT
Cancer Res; 1975 Jan; 35(1):189-93. PubMed ID: 1109788
[TBL] [Abstract][Full Text] [Related]
9. Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients.
Winters WD; Lamm DL
Cancer Res; 1981 Jul; 41(7):2672-6. PubMed ID: 7018669
[TBL] [Abstract][Full Text] [Related]
10. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
[TBL] [Abstract][Full Text] [Related]
11. Frequent immune responses to a cancer/testis antigen, CAGE, in patients with microsatellite instability-positive endometrial cancer.
Iwata T; Fujita T; Hirao N; Matsuzaki Y; Okada T; Mochimaru H; Susumu N; Matsumoto E; Sugano K; Yamashita N; Nozawa S; Kawakami Y
Clin Cancer Res; 2005 May; 11(10):3949-57. PubMed ID: 15897597
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies to human melanoma-associated antigens: an amplified enzyme-linked immunosorbent assay for the detection of antigen, antibody, and immune complexes.
Morgan AC; McIntyre RF
Cancer Res; 1983 Jul; 43(7):3155-9. PubMed ID: 6850625
[TBL] [Abstract][Full Text] [Related]
13. Enzyme-linked immunosorbent assay (ELISA) for antibodies to purified protein derivative of tuberculin (PPD). IgM-, IgA- and IgG- anti-PPD antibodies in active pulmonary tuberculosis.
Viljanen MK; Eskola J; Tala E
Eur J Respir Dis; 1982 May; 63(3):257-62. PubMed ID: 7095027
[TBL] [Abstract][Full Text] [Related]
14. [Effect of intra-lesional injection of tuberculin-active protein on metastatic nodules of human malignant melanoma].
Saida T
Nihon Hifuka Gakkai Zasshi; 1982 Nov; 92(13):1399-414. PubMed ID: 6984865
[No Abstract] [Full Text] [Related]
15. [Basis for a specific-active immunotherapy in malignant melanoma].
Mutzner PA; Stuhlmiller GM; Seigler HF; Stumpf WE; Sar M
Schweiz Med Wochenschr; 1981 Sep; 111(36):1322-5. PubMed ID: 7302537
[TBL] [Abstract][Full Text] [Related]
16. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
[TBL] [Abstract][Full Text] [Related]
17. Mycobacterial antibodies after tuberculin testing, BCG- vaccination, BCG-immunotherapy and against cross-reacting antigens in a solid-phase radioimmunoassay.
Mauch H; Brehmer W
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Mar; 251(3):380-8. PubMed ID: 6805156
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of lymphocyte proliferation assay to purified protein derivative, enzyme linked immunosorbant assay, and tuberculin hypersensitivity in Eales' disease.
Biswas J; Narain S; Roy S; Madhavan HN
Indian J Ophthalmol; 1997 Jun; 45(2):93-7. PubMed ID: 9475026
[TBL] [Abstract][Full Text] [Related]
19. Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: correlation with clinical response.
Ahn SS; Irie RF; Weisenburger TH; Jones PC; Juillard G; Roe DJ; Morton DL
Surgery; 1982 Aug; 92(2):362-7. PubMed ID: 7101129
[TBL] [Abstract][Full Text] [Related]
20. IFN-gamma responses in peptide-treated melanoma patients measured by an ELISPOT assay using allogeneic dendritic cells.
Gabrielsson S; Brichard V; Dhellin O; Dorval T; Bonnerot C
Anticancer Res; 2004; 24(1):171-7. PubMed ID: 15015594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
